Clinical applications of 18F-FDG in oncology

Journal of Nuclear Medicine Technology

Volumn 30, Issue 1, 2002, Pages 3-9

  Nabi, Hani A ^a   Zubeldia, José M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

18F FDG PET; Tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RECTUM CANCER; REVIEW; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036228762     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Wagner Jr lecture: Clinical PET - Role in diagnosis and management
2. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
3. Positron emission tomography: Applications in oncology
4. Targeting glucose transporters for tumor imaging: "Sweet" idea, "sour" result
5. On the origin of cancer cells
6. Lung tumor growth correlates with glucose metabolism measured by FDG PET
7. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study
8. Update in oncology
9. Lung cancer
10. Management of small cell lung cancer: Current state of the art
11. Lymph node staging in non-small-cell lung cancer with FDG-PET: A prospective study on 690 lymph node stations from 68 patients
12. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
13. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation
14. The usefulness of FDG positron emission tomography in the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with x-ray computed tomography
15. 18F-fluorodeoxyglucose positron emission tomography
16. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer?
17. Detecting recurrent or residual lung cancer with FDG-PET
18. 18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
19. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities
20. Analytical decision model for the cost-effective management of solitary pulmonary nodules
21. Patterns of recurrence after curative resection of carcinoma of the colon and rectum
22. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer
23. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography
24. 18F]fluorodeoxyglucose in recurrent colorectal cancer
25. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
26. ABC of clinical haematology: Malignant lymphomas and chronic lymphocytic leukaemia
27. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-gluose: Correlation with CT
28. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
29. Comparison of FDG-PET and gallium scan in staging and follow-up of patients with Hodgkin's disease
30. [F-18]-FDG-PET in primary staging of malignant lymphoma: First results of a multicenter study
31. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
32. FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy
33. Overview of skin cancer detection and prevention for the primary care physician
34. 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts
35. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose
36. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-d-glucose
37. Head and neck cancer
38. Head and neck (H&N) cancer: Value of F-18-FDG-PET in primary staging and suspicion of recurrence
39. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation
40. ABC of breast diseases, breast cancer-epidemiology, risk factors, and genetics
41. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases
42. The application of positron emission tomographic imaging with fluorodeoxyglucose to evaluation of breast disease
43. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
44. 18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
45. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
46. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
47. 18FDG Pet: Differing metabolic activity in osteoblasfic and osteolytic lesions
48. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
49. Epithelial ovarian carcinoma
50. 18F)FDG)
51. Classification of asymptomatic adnexal adrenal by ultrasound, magnetic resonance, and positron emission tomography
52. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
53. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
54. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
55. 18F]FDG positron emission tomography
56. FDG PET for detection and therapy control of metastatic germ cell tumor
57. Noninvasive grading of musculoskeletal tumors using PET